Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study
Journal of Thoracic Disease · 2023-02 · 15 (2) · 812-819
DOI: 10.21037/jtd-22-1528 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Thoracic Disease, 2023-02. Verfasst von Janneta Kisel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lane Fox Unit, Guy's and St Thomas' NHS Trust, London, UK. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder characterised by progressive muscle wasting impacting mobility, ventilation and cardiac function. Associated neuromuscular cardiomyopathy remains a major cause of morbidity and mortality. We investigated the effects of cardioprotective medications [angiotensin-converting enzyme inhibitors (ACE-I), beta-blockers] on clinical outcomes in DMD patients.
Methods
This was a retrospective cohort study (reference: 2021/12469) of DMD patients at a tertiary centre between 1993-2021 screening the electronic records for demographics, comorbidities, medication, disease specific features, echocardiography, hospitalisations, and ventilator use.
Results
A total of 68 patients were identified aged 27.4 (6.6) years, of which 52 were still alive. There was a difference in body mass index (BMI) between survivors and deceased patients [23.8 (5.9) vs. 19.9 (3.8) kg/m2, P=0.03]. Home mechanical ventilation (HMV) was required in 90% of patients, 85% had DMD associated cardiomyopathy. About 2/3 of all hospitalisations during the observation period were secondary to cardiopulmonary causes. The left ventricular ejection fraction (LVEF) at initial presentation was 44.8% (10.6%) and declined by 3.3% [95% confidence interval (CI): 0.4% to -7.0%] over the follow up period (P=0.002). A total of 61 patients were established on ACE-I for 75.9% (35.1%), and 62 were on beta-blockers for 73.6% (33.5%) of the follow up period. There was a significant LVEF decline in those taking ACE-I for limited periods compared to those permanently on ACE-I (P=0.002); a similar effect was recorded with beta-blockers (P=0.02).
Conclusions
Long-term use of ACE-I and beta-blockers is associated with a reduced decline in LVEF in patients with DMD and may be protective of adverse cardiovascular ill health.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lane Fox Unit, Guy's and St Thomas' NHS Trust, London, UK.
- Faculty of Life Sciences and Medicine, King's College London, London, UK.
Zitieren
APA
Kisel, J., Ballard, E., Suh, E. S., Hart, N., Kapetanakis, S., Srivastava, S., Marino, P., Murphy, P., & Steier, J. (2023). Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study. Journal of Thoracic Disease, 15(2), 812-819. https://doi.org/10.21037/jtd-22-1528
Vancouver
Kisel J, Ballard E, Suh ES, Hart N, Kapetanakis S, Srivastava S, et al. Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study. Journal of Thoracic Disease. 2023;15(2):812-819. doi:10.21037/jtd-22-1528
BibTeX
@article{Kisel2023,
author = {Kisel, Janneta and Ballard, Emily and Suh, Eui-Sik and Hart, Nicholas and Kapetanakis, Stam and Srivastava, Shelley and Marino, Philip and Murphy, Patrick and Steier, Joerg},
title = {Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study},
journal = {Journal of Thoracic Disease},
year = {2023},
volume = {15},
number = {2},
pages = {812--819},
doi = {10.21037/jtd-22-1528}
}
EUVIMED